Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001453687-24-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | RNAC | Davis Blaine | CFO | A - Grant | $0.00 | +2.42M | 2.42M | New | $0 |
| D | 2024-01-04 | 2024-01-02 | RNAC | Davis Blaine | CFO | A - Grant | $0.00 | +3.11M | 3.11M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 2,424,000 | $0.00 | 2,424,000 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2024-01-02 | A | A | 3,110,000 | $0.00 | 3,110,000 | D | $0.66 · — to 2034-01-01 | 3,110,000 Common Stock | (F2) This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. |